Showing results (411-420 of 584) with videos related to

Sort By:
Pageof 59
Annales D'Urologie|January 1, 1986
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]F Labrie, A Dupont, A Bélanger, et al.
The Journal of Steroid Biochemistry and Molecular Biology|August 12, 1998
Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cellsC Turgeon, S Gingras, M C Carrière, et al.
Journal of the National Cancer Institute|March 1, 1977
Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorsP A Kelly, J Asselin, M G Caron, et al.
Endocrinology|May 16, 1998
Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized miceS Luo, A Sourla, C Labrie, et al.
Clinical Endocrinology|January 1, 1986
Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogenR St-Arnaud, R Lachance, S J Kelly, et al.
The Journal of Investigative Dermatology|November 1, 1995
Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activityC Chen, L A Puy, J Simard, et al.
Bioorganic & Medicinal Chemistry|January 1, 1996
Vinyl fluoride as a mimic of the "intermediate' enol form in the 5 alpha-reductase transformation: synthesis and in vitro activity of (N-1',1'-dimethylethyl)-3-haloandrost-3,5-diene-17 beta-carboxamidesX Li, S M Singh, V Luu-The, et al.
Cytogenetics and Cell Genetics|January 1, 1995
Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locusJ Morissette, E Rhéaume, J F Leblanc, et al.
Anticancer Research|March 1, 1994
Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide)M Koutsilieris, A Dupont, J Gomez, et al.
The Prostate|January 1, 1984
The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a reviewJ P Raynaud, C Bonne, M Moguilewsky, et al.
Pageof 59